Department of Theriogenology and Biotechnology, Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea.
Research and Development Center, Einocle Inc., Seoul 02841, Republic of Korea.
Int J Mol Sci. 2023 Jan 30;24(3):2618. doi: 10.3390/ijms24032618.
Canine mammary gland tumor (CMT) is the most frequently diagnosed neoplasm in intact female dogs. As prognosis depends on the malignancy of tumors and metastasis levels, early and accurate diagnosis are crucial for prolongation of life expectancy. The genetic similarity of dogs with humans in addition to environmental and physiological similarities make them ideal models for the study of cancer. In this study, we analyzed differentially expressed microRNAs followed by RNA-Seq to investigate the alterations in mRNA levels based on the malignancy (benign, malignant) and the biopsy locations (tumors, surrounding normal tissues). We identified multiple breast cancer-related genes regardless of malignancy. We found cfa-miR-503 to be the only miRNA that showed altered expression in response to malignancy in CMTs. Although further validation is needed, cfa-miR-503 could be used as a potential diagnostic biomarker as well as a potential RNA-based anti-tumor drug in malignant CMTs.
犬乳腺肿瘤(CMT)是未绝育雌性犬中最常诊断出的肿瘤。由于预后取决于肿瘤的恶性程度和转移水平,因此早期和准确的诊断对于延长预期寿命至关重要。狗与人类在遗传上的相似性,加上环境和生理上的相似性,使它们成为癌症研究的理想模型。在这项研究中,我们分析了差异表达的 microRNAs,然后进行 RNA-Seq 分析,以根据恶性程度(良性、恶性)和活检部位(肿瘤、周围正常组织)来研究 mRNA 水平的变化。我们发现了多个与乳腺癌相关的基因,而不论其恶性程度如何。我们发现 cfa-miR-503 是唯一一种在 CMT 中对恶性反应表现出改变表达的 miRNA。尽管需要进一步验证,但 cfa-miR-503 可用作恶性 CMT 的潜在诊断生物标志物和潜在的基于 RNA 的抗肿瘤药物。